JX7 Stock Overview
A medical device company, focuses on the provision of various solutions to enhance the health and wellbeing of people living with diabetes in the United States and internationally. More details
| Snowflake Score | |
|---|---|
| Valuation | 6/6 |
| Future Growth | 3/6 |
| Past Performance | 2/6 |
| Financial Health | 0/6 |
| Dividends | 2/6 |
Rewards
Risk Analysis
+ 1 more risk
My Notes
Capture your thoughts, links and company narrative
Embecta Corp. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$13.70 |
| 52 Week High | US$19.90 |
| 52 Week Low | US$9.25 |
| Beta | 1.15 |
| 1 Month Change | -22.60% |
| 3 Month Change | 3.79% |
| 1 Year Change | 2.24% |
| 3 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | -51.07% |
Recent News & Updates
Recent updates
Shareholder Returns
| JX7 | DE Medical Equipment | DE Market | |
|---|---|---|---|
| 7D | -9.3% | -2.4% | -0.6% |
| 1Y | 2.2% | -4.7% | 14.8% |
Return vs Industry: JX7 exceeded the German Medical Equipment industry which returned -4.7% over the past year.
Return vs Market: JX7 underperformed the German Market which returned 14.8% over the past year.
Price Volatility
| JX7 volatility | |
|---|---|
| JX7 Average Weekly Movement | 13.6% |
| Medical Equipment Industry Average Movement | 6.8% |
| Market Average Movement | 4.8% |
| 10% most volatile stocks in DE Market | 11.5% |
| 10% least volatile stocks in DE Market | 2.6% |
Stable Share Price: JX7's share price has been volatile over the past 3 months compared to the German market.
Volatility Over Time: JX7's weekly volatility (14%) has been stable over the past year, but is still higher than 75% of German stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1924 | 2,100 | Dev Kurdikar | www.embecta.com |
Embecta Corp., a medical device company, focuses on the provision of various solutions to enhance the health and wellbeing of people living with diabetes in the United States and internationally. The company’s products include pen needles, syringes, and safety injection devices, as well as digital applications to assist people with managing patient’s diabetes. It primarily sells its products to wholesalers and distributors.
Embecta Corp. Fundamentals Summary
| JX7 fundamental statistics | |
|---|---|
| Market cap | €783.55m |
| Earnings (TTM) | €55.63m |
| Revenue (TTM) | €1.06b |
14.1x
P/E Ratio0.7x
P/S RatioIs JX7 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| JX7 income statement (TTM) | |
|---|---|
| Revenue | US$1.11b |
| Cost of Revenue | US$395.10m |
| Gross Profit | US$712.60m |
| Other Expenses | US$654.40m |
| Earnings | US$58.20m |
Last Reported Earnings
Dec 31, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | 1.00 |
| Gross Margin | 64.33% |
| Net Profit Margin | 5.25% |
| Debt/Equity Ratio | -200.9% |
How did JX7 perform over the long term?
See historical performance and comparisonDividends
4.3%
Current Dividend Yield60%
Payout RatioDoes JX7 pay a reliable dividends?
See JX7 dividend history and benchmarks| Embecta dividend dates | |
|---|---|
| Ex Dividend Date | Feb 28 2025 |
| Dividend Pay Date | Mar 14 2025 |
| Days until Ex dividend | 5 days |
| Days until Dividend pay date | 19 days |
Does JX7 pay a reliable dividends?
See JX7 dividend history and benchmarksCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/02/22 22:30 |
| End of Day Share Price | 2025/02/21 00:00 |
| Earnings | 2024/12/31 |
| Annual Earnings | 2024/09/30 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Embecta Corp. is covered by 9 analysts. 4 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Travis Steed | BofA Global Research |
| Travis Steed | BofA Global Research |
| Marie Thibault | BTIG |